Rnai Technology Market Size, Share, Trends, And Forecast, 2026-2033 Market To Reach $9.5 Billion As Precision Therapeutics Unlock Oncology And Rare Disease Growth
Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- "RNAi Technology Market Size, Share & Trends Analysis Report 2026-2033" has been added to ResearchAndMarkets.com's offering.
The global RNAi technology market was valued at USD 3.3 billion in 2025 and is expected to increase from USD 3.7 billion in 2026 to USD 9.5 billion by 2033. This expansion represents a compound annual growth rate of 14.6% from 2026 to 2033. Rising demand for advanced therapeutic technologies, expanding drug discovery programs, and the increasing prevalence of autoimmune diseases, rare disorders, and cancer are among the principal factors supporting market growth.
North America led the global RNAi technology market in 2025, accounting for 38.3% of total revenue. The region's position is supported by substantial biotechnology and pharmaceutical research activity, continued investment in RNA-based drug development, and the presence of established industry participants. Academic institutions, research organizations, and contract service providers also contribute to the region's strong commercialization environment.
The report provides revenue forecasts and strategic analysis across product & service, application, end use, and regional segments. It evaluates market developments and emerging trends across the principal sub-segments from 2021 to 2033, enabling stakeholders to assess revenue potential, competitive conditions, and future growth opportunities.
Product & Service Segmentation
- Products siRNA products miRNA products Other RNAi products Services
RNAi products represent an important component of the market as pharmaceutical and biotechnology companies expand their pipelines and investigate new therapeutic applications. Services also support market development by providing specialized research, development, testing, and manufacturing capabilities to organizations seeking external expertise.
Application Segmentation
- Drug Discovery & Development Neurology Oncology Infectious Diseases Metabolic Diseases Other therapeutic applications Functional Genomics Other applications
Drug Discovery & Development remains a central application area, with RNAi technology increasingly incorporated into target validation, therapeutic research, and pipeline advancement. Oncology, neurology, infectious diseases, and metabolic diseases offer significant opportunities as researchers pursue highly targeted approaches for complex conditions. Functional genomics is another key application, supporting the investigation of gene function and biological pathways.
End Use Segmentation
- Pharmaceutical & Biotechnology Companies Academic & Research Institutes CROs & CMOs
Pharmaceutical & Biotechnology Companies are major users of RNAi technology due to growing investment in novel therapeutics and precision medicine. Academic & Research Institutes support early-stage innovation and translational research, while CROs & CMOs provide outsourced development, clinical, and manufacturing services that can accelerate product advancement.
Regional Coverage
- North America: U.S., Canada, and Mexico Europe: UK, Germany, France, Italy, Spain, Denmark, Sweden, and Norway Asia Pacific: Japan, China, India, Australia, Thailand, and South Korea Latin America: Brazil and Argentina Middle East and Africa (MEA): South Africa, Saudi Arabia, UAE, and Kuwait
The regional analysis helps organizations compare market performance, identify high-growth countries, and evaluate local opportunities. In addition to North America's established position, Asia Pacific and other developing markets may benefit from expanding biomedical research, improving healthcare infrastructure, and increased participation in biotechnology innovation.
Strategic Value of the Report
- Comprehensive analysis of major RNAi technology market segments and regions Assessment of the competitive landscape and market presence of key participants Evaluation of trends and growth drivers shaping the industry's future Segment-level and regional revenue forecasts for market planning Insights into growth opportunities, competition strategies, and market share Coverage of product innovation and emerging commercial opportunities Actionable intelligence to support investment, expansion, and business development decisions
The report is designed to help industry participants, investors, researchers, and strategic decision-makers evaluate the global RNAi technology market. Its combination of revenue analysis, competitive intelligence, innovation tracking, and forward-looking forecasts supports informed planning while helping organizations identify potential revenue streams and maintain a competitive position in a rapidly evolving biotechnology sector.
Key Topics Covered:
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Products & Service Segment
1.1.1.2. Application Segment
1.1.1.3. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. The internal database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis:
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. List of Secondary Sources
1.9.3. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Technological Advancements in RNAi Techniques
3.2.1.2. Increasing Application of RNAi Technology in Research and Medicine
3.2.1.3. Growing Demand for Precision Therapeutics
3.2.2. Market Restraint Analysis
3.2.2.1. High Development and Manufacturing Costs
3.2.2.2. Challenges Associated with Efficient RNAi Delivery Systems
3.2.2.3. Off-Target Effects and Safety Concerns
3.2.3. Market Opportunities Analysis
3.2.4. Market Challenges Analysis
3.3. Industry Analysis Tools
3.3.1. Porter's Five Forces Analysis
3.3.2. PESTLE Analysis
Chapter 4. Product & Service Business Analysis
4.1. Segment Dashboard
4.2. RNAi Technology Market: Product & Service Movement Analysis
4.3. Products
4.3.1. Products Market, 2021-2033 (USD Million/Billion)
4.3.2. siRNA Products
4.3.2.1. siRNA Products Market, 2021-2033 (USD Million/Billion)
4.3.3. miRNA Products
4.3.3.1. miRNA Products Market, 2021-2033 (USD Million/Billion)
4.3.4. Others
4.3.4.1. Others Market, 2021-2033 (USD Million/Billion)
4.4. Services
4.4.1. Services Market, 2021-2033 (USD Million/Billion)
Chapter 5. Application Business Analysis
5.1. Segment Dashboard
5.2. RNAi Technology Market: Application Movement Analysis
5.3. Drug Discovery & Development
5.3.1. Drug Discovery & Development Market, 2021-2033 (USD Million/Billion)
5.3.2. Neurology
5.3.2.1. Neurology Market, 2021-2033 (USD Million/Billion)
5.3.3. Oncology
5.3.3.1. Oncology Market, 2021-2033 (USD Million/Billion)
5.3.4. Infectious Diseases
5.3.4.1. Infectious Diseases Market, 2021-2033 (USD Million/Billion)
5.3.5. Metabolic Diseases
5.3.5.1. Metabolic Diseases Market, 2021-2033 (USD Million/Billion)
5.3.6. Others
5.3.6.1. Others Market, 2021-2033 (USD Million/Billion)
5.4. Functional Genomics
5.4.1. Functional Genomics Market, 2021-2033 (USD Million/Billion)
5.5. Others
5.5.1. Others Market, 2021-2033 (USD Million/Billion)
Chapter 6. End Use Business Analysis
6.1. Segment Dashboard
6.2. RNAi Technology Market: End Use Movement Analysis
6.3. Pharmaceutical & Biotechnology Companies
6.3.1. Pharmaceutical & Biotechnology Companies Market, 2021-2033 (USD Million/Billion)
6.4. Academic & Research Institutes
6.4.1. Academic & Research Institutes Market, 2021-2033 (USD Million/Billion)
6.5. CROs & CMOs
6.5.1. CROs & CMOs Market, 2021-2033 (USD Million/Billion)
Chapter 7. Regional Business Analysis
7.1. RNAi Technology Market Share by Region, 2025 & 2033
7.2. North America
7.2.1. North America RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. U.S. RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Canada RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.2.4. Mexico
7.2.4.1. Key Country Dynamics
7.2.4.2. Competitive Scenario
7.2.4.3. Regulatory Framework
7.2.4.4. Mexico RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.3. Europe
7.3.1. Europe RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. UK RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Germany RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Framework
7.3.4.4. France RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Regulatory Framework
7.3.5.4. Italy RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Regulatory Framework
7.3.6.4. Spain RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Regulatory Framework
7.3.7.4. Denmark RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Regulatory Framework
7.3.8.4. Sweden RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Regulatory Framework
7.3.9.4. Norway RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.4. Asia Pacific
7.4.1. Asia Pacific RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. Japan RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. China RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. India RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Regulatory Framework
7.4.5.4. Australia RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Regulatory Framework
7.4.6.4. Thailand RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Framework
7.4.7.4. South Korea RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.5. Latin America
7.5.1. Latin America RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Brazil RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.5.3. Argentina
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Argentina RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.6. MEA
7.6.1. MEA RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. South Africa RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Saudi Arabia RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. UAE RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Kuwait RNAi Technology Market, 2021 - 2033 (USD Million/Billion)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share/ Position Analysis, 2025
8.4. Company Profiles/Listing
8.4.1. Thermo Fisher Scientific, Inc.
8.4.1.1. Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Merck KGaA
8.4.2.1. Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Creative Biolabs
8.4.3.1. Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. GenScript
8.4.4.1. Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Revvity
8.4.5.1. Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Promega Corporation
8.4.6.1. Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. OriGene Technologies, Inc.
8.4.7.1. Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Altogen Biosystems
8.4.8.1. Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Danaher
8.4.9.1. Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Bioneer Corporation
8.4.10.1. Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives
List of Tables [95]
List of Figures [65]
Companies Featured
- Thermo Fisher Scientific, Inc. Merck KGaA Creative Biolabs GenScript Revvity Promega Corporation OriGene Technologies, Inc. Altogen Biosystems Danaher Bioneer Corporation
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment